GlobeNewswire by notified

FocusCura subsidiary Luscii will continue as independent company with partner OMRON Healthcare to accelerate their international expansion

Share

Joining forces supports hospitals in moving care towards the home

AMSTERDAM, The Netherlands, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Luscii, the e-health application for remote monitoring developed by FocusCura, is set to continue as an independent company. Healthcare entrepreneur and FocusCura founder Daan Dohmen has acquired the majority of the shares and formed a strategic partnership with OMRON Healthcare, known among other things as the largest manufacturer of blood pressure monitors in the world. Part of this cooperation includes an investment, with which Luscii can accelerate its development further in the coming years. OMRON will also support launches in more European countries, as the two companies announced today.

Remote monitoring
With Luscii, chronically ill patients can be monitored remotely. Remote monitoring via the Luscii app, in combination with smart algorithms, warns the patient's healthcare network in the event of a deteriorating health situation. Direct contact is then made with the doctor or nurse via the app. Through this method, hospital visits, diagnostics and admissions can be prevented.

Luscii was conceived by a team at FocusCura. They were given an office in Amsterdam and space to attract technical talent from all over the world. That focus paid off. Today, Luscii is in use in almost half of all the hospitals in the Netherlands and the concept is reimbursed by 94% of insurers. "This is just the beginning," says Dohmen. "We are now active in the Netherlands, the Nordics and the UK, and we will continue until all chronic patients have access to remote monitoring in their own region."

OMRON Healthcare
The collaboration with OMRON will accelerate that ambition. OMRON’s blood pressure monitors are the most widely used in scientific studies worldwide. With more than 200 million monitors in use by patients and care professionals, the manufacturer is number 1 in the field of medical remote monitoring. Dohmen: "The connection with OMRON immediately launches us in places where we can make a difference." The two companies have been working together for some time, through, among other things, the connection of OMRON equipment to the Luscii app for heart, lung and vascular measurements at home, and with the development of artificial intelligence (AI) that provides doctors, nurses and patients with treatment advice based on remote monitoring.

For OMRON, the collaboration is logical, says André van Gils, CEO of the European-American branch of the Japanese company. "Luscii is an international leader in the movement to bring hospital care to the home. We will help to expand that position and use our network, technology and knowledge to aid healthcare providers in meeting the rising demand for care. This partnership supports our mission to help realize healthy and comfortable lives for everyone, without any compromises."

Breakthrough
In European countries, efforts have been made for some time to make e-health available for chronic patients in order to prevent hospital visits and admissions. Despite that, a breakthrough is yet to be achieved. However, Luscii is one of the first digital healthcare concepts capable of bridging the important barriers in implementation. For example, Luscii successfully managed to integrate with large electronic patient records and secured reimbursement from insurers for their concept. Scientific research showed that using Luscii for specific target groups, such as patients with COPD, heart failure and resistant hypertension, can reduce hospital costs significantly and make patients feel safer.

NOTE FOR EDITORS
For more information, interview requests and visual material, please contact Jessica Juckes. Email OmronHealthcareGlobal@hotwireglobal.com Phone: +44 (0) 207 608 4683

Images (copyright free for publication):
Images from patient performing remote monitoring with the Luscii app and OMRON meter as well as the Luscii logo and screens can be downloaded here: Download presskit (https://luscii.com/downloads/).

About Luscii
Luscii has the ambition to organise chronic care with the aid of technology, so that visits and admissions to the hospital could be prevented. With Luscii's digital healthcare concept and apps for iOS, Android and web, doctors and nurses can guide their patients remotely and directly from their electronic patient record via remote monitoring and video calling, with the support of smart algorithms. Luscii was conceived by a team within FocusCura, and became an independent company at the end of 2018. Today, Luscii is reimbursed by 94% of insurers and is active in almost half of Dutch hospitals, in the Nordics and in the UK. Luscii is an Apple Mobility Partner and has a global, strategic partnership with OMRON Healthcare. More information can be found at: www.luscii.com.

About OMRON Healthcare
As a world leader in innovative and clinically proven medical equipment for health monitoring and treatment, OMRON Healthcare is committed to offering everyone a fuller and richer life without any compromises. OMRON Healthcare is the global market leader in electronic blood pressure monitors, with more than 200 million units sold, and nebulizers used for the treatment of respiratory diseases. The company’s other major product categories include pain relievers, electronic thermometers and scales for body analysis. For decades, OMRON products have helped prevent, treat and control medical conditions, both at home and in clinical settings, in more than 110 countries worldwide. The head office of the OMRON Healthcare Group is located in Kyoto (Japan). OMRON Healthcare Europe Ltd. comprises the healthcare branch for Europe, Russia, the Middle East and Africa, which provides services to clients in more than 74 countries. 

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Correction to Company announcement – No. 23 / 202419.4.2024 22:20:51 CEST | Press release

Correction to Company announcement – No. 23 / 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has a correction to company announcement No. 23 /2024, April 19, 2024 - regarding transactions in Zealand’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons it was reported that member of the management, Henriette Wennicke, was allocated a total of 8,008 restricted stock units with a total value of DKK 9,577,568.00. The correct number was a total of 8,008 restricted stock units with a total value of DKK 4,788,784.00. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10

Nokia Corporation: Repurchase of own shares on 19.04.202419.4.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 19 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 19.04.2024 Espoo, Finland – On 19 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL430,8933.30CEUX--BATE--AQEU--TQEX--Total430,8933.30 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

Landsbankinn hf.: Results of the 2024 AGM of Landsbankinn19.4.2024 20:48:08 CEST | Press release

The annual general meeting (AGM) of Landsbankinn, held on 19 April 2024, agreed to pay a dividend amounting to ISK 16,535 million to shareholders. The dividend is equivalent to 50% of 2023 profits. The dividend will be paid in two instalments, firstly on 24 April 2024 and secondly on 16 October 2024. As a result, total dividend paid by the Bank in 2013-2024 amounts to ISK 191.7 billion. At the AGM, held in Reykjastræti 6, Helga Björk Eiríksdóttir, Chairman of the Board of Directors, delivered the report from the Board for 2023. Lilja Björk Einarsdóttir, CEO, spoke of the Bank’s operation, strategy and activities in the past operating year. The annual financial statement for the past operating year was approved, as was the proposed Remuneration Policy and remuneration to Directors of the Board. The AGM elected the Auditor General (Ríkisendurskoðun) as auditor of Landsbankinn hf. for the 2024 operating year. The Auditor General, in accordance with an authorisation to outsource tasks, and

SKEL fjárfestingafélag hf.: Styrkás finalizes the purchase of Stólpi Gámar ehf. and affiliated companies.19.4.2024 19:20:57 CEST | Press release

Reference is made to the announcement dated 31 January 2024, regarding Styrkás hf., a company 69.64% owned by SKEL fjárfestingafélag hf., signing a purchase agreement to acquire 100% of the shares in six subsidiaries of Máttarstólpi ehf. The purchase agreement was subject to the approval of the Competition Authority. The transaction was finalized today with payment of purchase price and delivering of shares in the following companies: - Stólpi Gámar ehf., id. 460121-1590, Klettagörðum 5, 104 Reykjavík: - Stólpi Smiðja ehf., id. 460121-1750, Klettagörðum 5, 104 Reykjavík; - Klettskjól ehf., id. 460121-0510, Klettagörðum 5, 104 Reykjavík; - Stólpi ehf., 460121-0430, Klettagörðum 5, 104 Reykjavík; - Tjónaþjónustan ehf., id. 460121-1670, Klettagörðum 5, 104 Reykjavík; - Alkul ehf., id. 491020-0830, Haukdælabraut 48, 113 Reykjavík. collectively referred to as "the sold companies". These companies will continue to be operated on a consolidated basis. The Enterprise value of the sold companie

HiddenA line styled icon from Orion Icon Library.Eye